Bullous pemphigoid is the most common autoimmune ... Exclusion criteria were predominant or exclusive mucosal involvement and treatment with oral or topical corticosteroids, dapsone, or ...

Oral blisters are rare. Instead, blisters tend to arise more in the flexures of joints like inside the elbows or behind the knees. The pathogenesis of Bullous pemphigoid is characterized by the ...

Pemphigoid is a family of rare autoimmune conditions that causes blistering and rashes on the skin and mucous membranes. The body mistakenly sends antibodies to bind to cells in the skin.

Mucous membrane pemphigoid (MMP) encompasses a heterogeneous ... Of these, the most commonly affected are the oral mucosa and conjunctiva. In less common cases the skin may also be involved.

EM minor rarely involves mucosa; the more serious EM major often involves mucosa (in 70% of cases), unlike BP. Histologic findings involve many that are not seen in BP, such as edematous papillary ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin disorder bullous pemphigoid (BP). The US Food ...

11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Dupixent ® (dupilumab) pivotal trial (ADEPT) in bullous pemphigoid (BP) met the ...

Bullous pemphigoid (BP), usually seen in the elderly, is the most common autoimmune blistering disease. The various clinical presentations of BP, similar and associated diseases, and the ...